130 related articles for article (PubMed ID: 28625368)
1. Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design.
Violi F; Targher G; Vestri A; Carnevale R; Averna M; Farcomeni A; Lenzi A; Angelico F; Cipollone F; Pastori D
Am Heart J; 2017 Jul; 189():120-127. PubMed ID: 28625368
[TBL] [Abstract][Full Text] [Related]
2. Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease.
Pastori D; Pignatelli P; Perticone F; Sciacqua A; Carnevale R; Farcomeni A; Basili S; Corazza GR; Davì G; Lip GYH; Violi F;
Int J Cardiol; 2016 Nov; 223():619-624. PubMed ID: 27565838
[TBL] [Abstract][Full Text] [Related]
3. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
Heerspink HJ; Persson F; Brenner BM; Chaturvedi N; Brunel P; McMurray JJ; Desai AS; Solomon SD; Pfeffer MA; Parving HH; de Zeeuw D
Lancet Diabetes Endocrinol; 2016 Apr; 4(4):309-17. PubMed ID: 26774608
[TBL] [Abstract][Full Text] [Related]
4. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
Goicoechea M; de Vinuesa SG; Quiroga B; Verde E; Bernis C; Morales E; Fernández-Juárez G; de Sequera P; Verdalles U; Delgado R; Torres A; Arroyo D; Abad S; Ortiz A; Luño J
Cardiovasc Drugs Ther; 2018 Jun; 32(3):255-263. PubMed ID: 29943364
[TBL] [Abstract][Full Text] [Related]
5. Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
de Boer IH; Zelnick LR; Ruzinski J; Friedenberg G; Duszlak J; Bubes VY; Hoofnagle AN; Thadhani R; Glynn RJ; Buring JE; Sesso HD; Manson JE
JAMA; 2019 Nov; 322(19):1899-1909. PubMed ID: 31703120
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
[TBL] [Abstract][Full Text] [Related]
7. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
[TBL] [Abstract][Full Text] [Related]
8. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
[TBL] [Abstract][Full Text] [Related]
9. Early low-dose erythropoiesis-stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo-controlled trial.
Fliser D; Dellanna F; Koch M; Wiggenhauser A;
Nephrol Dial Transplant; 2017 Feb; 32(2):279-287. PubMed ID: 28186540
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
[TBL] [Abstract][Full Text] [Related]
11. Urinary Potassium Excretion and Renal and Cardiovascular Complications in Patients with Type 2 Diabetes and Normal Renal Function.
Araki S; Haneda M; Koya D; Kondo K; Tanaka S; Arima H; Kume S; Nakazawa J; Chin-Kanasaki M; Ugi S; Kawai H; Araki H; Uzu T; Maegawa H
Clin J Am Soc Nephrol; 2015 Dec; 10(12):2152-8. PubMed ID: 26563378
[TBL] [Abstract][Full Text] [Related]
12. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials.
Lambers Heerspink HJ; Tighiouart H; Sang Y; Ballew S; Mondal H; Matsushita K; Coresh J; Levey AS; Inker LA
Am J Kidney Dis; 2014 Dec; 64(6):860-6. PubMed ID: 25441439
[TBL] [Abstract][Full Text] [Related]
13. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
15. Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study.
Greene T; Teng CC; Inker LA; Redd A; Ying J; Woodward M; Coresh J; Levey AS
Am J Kidney Dis; 2014 Dec; 64(6):867-79. PubMed ID: 25441440
[TBL] [Abstract][Full Text] [Related]
16. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
Lambers Heerspink HJ; Chertow GM; Akizawa T; Audhya P; Bakris GL; Goldsberry A; Krauth M; Linde P; McMurray JJ; Meyer CJ; Parving HH; Remuzzi G; Christ-Schmidt H; Toto RD; Vaziri ND; Wanner C; Wittes J; Wrolstad D; de Zeeuw D
Nephrol Dial Transplant; 2013 Nov; 28(11):2841-50. PubMed ID: 24169612
[TBL] [Abstract][Full Text] [Related]
17. Gain in adiposity over 3 years is associated with progressive renal decline in multi-ethnic South-east Asians with type 2 diabetes.
Moh MC; Sum CF; Tavintharan S; Ang K; Kwan PY; Lee SBM; Tang WE; Lim SC
J Diabetes; 2019 Apr; 11(4):316-325. PubMed ID: 30178527
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial.
Hadjadj S; Cooper ME; Steubl D; Petrini M; Hantel S; Mattheus M; Wanner C; Thomas MC
Kidney Med; 2024 Mar; 6(3):100783. PubMed ID: 38419787
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.
Falco A; Salvati F; Vitacolonna E; Avellone G; Pinto A; Di Febbo C; Ballone E; Di Nicola M; Ciabattoni G; Davì G
Atherosclerosis; 2005 Dec; 183(2):329-35. PubMed ID: 16285996
[TBL] [Abstract][Full Text] [Related]
20. Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
de Zeeuw D; Akizawa T; Agarwal R; Audhya P; Bakris GL; Chin M; Krauth M; Lambers Heerspink HJ; Meyer CJ; McMurray JJ; Parving HH; Pergola PE; Remuzzi G; Toto RD; Vaziri ND; Wanner C; Warnock DG; Wittes J; Chertow GM
Am J Nephrol; 2013; 37(3):212-22. PubMed ID: 23467003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
